References
- 1. Marcocci C, Bartalena L, Bogazzi F, Panicucci M, Pinchera A. Studies on the occurrence of ophthalmopathy in Graves' disease. Acta Endocrinol (Copenh). 1989;120(4):473-8.10.1530/acta.0.1200473
- 2. Bartley GB, Fatourechi V, Kadrmas EF, et al. Clinical features of Graves' ophthalmopathy in an incidence cohort. Am J Ophthalmol. 1996;121(3):284-90.10.1016/S0002-9394(14)70276-4
- 3. Mohaseb K, Linder M, Rootman J, et al. Development and validation of a patient symptom questionnaire to facilitate early diagnosis of thyroidassociated orbitopathy in graves' disease. Orbit. 2008;27(6):419-25.10.1080/0167683080241456619085296
- 4. Dickinson AJ, Perros P. Controversies in the clinical evaluation of active thyroid-associated orbitopathy: use of a detailed protocol with comparative photographs for objective assessment. Clin Endocrinol (Oxf). 2001;55(3):283-303.10.1046/j.1365-2265.2001.01349.x11589671
- 5. Eckstein AK, Lösch C, Glowacka D, et al. Euthyroid and primarily hypothyroid patients develop milder and significantly more asymmetrical Graves ophthalmopathy. Br J Ophthalmol. 2009;93(8):1052-6.10.1136/bjo.2007.13726519221109
- 6. 6.Cozma I, Cozma LS, Boyce RL - Variation in thyroid status in patients with Graves' orbitopathy. Acta Endo (Buc). 2009;5(2):191-198.10.4183/aeb.2009.191
- 7. Mourits MP, Koornneef L, Wiersinga WM, et al. Clinical criteria for the assessment of disease activity in Graves' ophthalmopathy: a novel approach. Br J Ophthalmol. 1989;73(8):639-44.10.1136/bjo.73.8.63910418352765444
- 8. Terwee CB, Prummel MF, Gerding MN, et al. Measuring disease activity to predict therapeutic outcome in Graves' ophthalmopathy. Clin Endocrinol (Oxf). 2005;62(2):145-55.10.1111/j.1365-2265.2005.02186.x15670189
- 9. Prummel MF, Bakker A, Wiersinga WM, et al. Multi-center study on the characteristics and treatment strategies of patients with Graves' orbitopathy: the first European Group on Graves' Orbitopathy experience. Eur J Endocrinol. 2003;148(5):491-5.10.1530/eje.0.148049112720530
- 10. Dolman PJ. Evaluating Graves' orbitopathy. Best Pract Res Clin Endocrinol Metab. 2012;26(3):229-48.10.1016/j.beem.2011.11.00722632361
- 11. Gerding MN, van der Meer JW, Broenink M, et al. Association of thyrotrophin receptor antibodies with the clinical features of Graves' ophthalmopathy. Clin Endocrinol (Oxf). 2000;52(3):267-71.10.1046/j.1365-2265.2000.00959.x10718823
- 12. Eckstein AK, Johnson KT, Thanos M, Esser J, Ludgate M. Current insights into the pathogenesis of Graves' orbitopathy. Horm Metab Res. 2009;41(6):456-464.10.1055/s-0029-122093519530272
- 13. Bellur SP, Bahn RS, Smith TJ. Current Perspective on the Pathogenesis of Graves’ Disease and Ophthalmopathy. Endocrine Reviews. 2003;24(6):802-835.10.1210/er.2002-002014671007
- 14. Pappa A, Lawson JMM, Calder V, et al. T cells and fibroblasts in affected extraocular muscles in early and late thyroid associated ophthalmopathy. Br J Ophthalmol. 2000;84:517-522.10.1136/bjo.84.5.517172344910781517
- 15. Han R, Smith TJ. Induction by IL-1β of Tissue Inhibitor of Metalloproteinase-1 in Human Orbital Fibroblasts: Modulation of Gene Promoter Activity by IL-4 and IFN-γ. J. Immun. 2005;174(5):3072-3079.
- 16. Cawood TJ, Moriarty P, O’Farrelly P, O’Shea D. The effects of tumour necrosis factor-α and interleukin1 on an in vitro model of thyroidassociated ophthalmopathy; contrasting effects on adipogenesis. Eur J Endocrinol. 2006;155:395-403.10.1530/eje.1.0224216914593
- 17. Krassas GE, Wiersinga W. Smoking and autoimmune thyroid disease: the plot thickens. Eur J Endocrinol. 2006;15:4777-78.
- 18. Cawood TJ, Moriarty P, O’Farrelly P, O’Shea P. Smoking and Thyroid- Associated Ophthalmopathy: A Novel Explanation of the Biological Link. J Clin Endocrinol Metab. 2007;92:159-64.10.1210/jc.2006-182417047020
- 19. Bartalena L, Baldeschi L, Dickinson A, et al. Consensus statement of the European Group on Graves' orbitopathy (EUGOGO) on management of GO Eur J Endocrinol. 2008;15:8273-285.
- 20. Wakelkamp IMMJ, Bakker O, Baldeschi L, Wiersinga WM, Prummel MF. TSH-R expression and cytokine profile in orbital tissue of active vs. inactive Graves’ ophthalmopathy patients. Clin Endocrin. 2003;58(3):280-287.
- 21. Szucs-Farkas Zs, Toth J, Kollar J, et al. Volume Changes in Intra- and Extraorbital Compartments in Patients with Graves' Ophthalmopathy: Effect of Smoking. Thyroid. 2005;15(2):146-151.10.1089/thy.2005.15.14615753674
- 22. ThorntonJ, Kelly SP, Harrison RA, Edwards R. Cigarette smoking and thyroid eye disease: a systematic review. Eye. 2007;21:1135-1145.10.1038/sj.eye.670260316980921
- 23. Wiersinga WM and Bartalena L. Epidemiology and Prevention of Graves' Ophthalmopathy. Thyroid. 2002;12(10):855-860.10.1089/10507250276101647612487767
- 24. de Carli M, D'Elios MM, Mariotti S, et al. Cytolytic T cells with Th1-like cytokine profile predominate in retroorbital lymphocytic infiltrates of Graves' ophthalmopathy. J Clin Endocrin Metab. 1999;77:51120-1124.
- 25. Gianoukakis AG, Khadavi N, Smith TJ. Cytokines, Graves' Disease, and Thyroid-Associated Ophthalmopathy. Thyroid. 2008;18(9):953-95. 10.1089/thy.2007.0405287949018713026